Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 6/2013

01.06.2013 | Article

Correlation of methicillin-resistant Staphylococcus aureus vancomycin minimal inhibitory concentration results by Etest and broth microdilution methods with population analysis profile: lack of Etest overestimation of the MIC

verfasst von: R. Khatib, K. Riederer, S. Shemes, A. C. Musta, S. Szpunar

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) vancomycin minimum inhibitory concentrations (V-MICs) are sometimes reported to be higher according to Etest versus broth microdilution (BMD). These observations are often interpreted as an Etest overestimation of the actual MIC. We measured V-MIC of 484 MRSA blood isolates using Etest, BMD, and a modified BMD (M-BMD) with incremental dilutions parallel to the Etest scale, correlated the results with population analysis profile–area under the curve (PAP-AUC). All MIC tests were done in parallel. The mean V-MIC was comparable (1.83 ± 0.44 [Etest], 1.88 ± 0.67 [BMD] and 1.75 ± 0.57 mg/L [M-BMD]; p = 0.9 [ANOVA]). The V-MICs/PAP-AUC correlation coefficient was 0.555 (Etest), 0.513 (BMD), and 0.586 (M-BMD). Etest MICs were equal (44.2 %), one dilution higher (21.9 %), two dilutions higher (2.5 %), one dilution lower (29.8 %), and two dilutions lower (1.6 %) than BMD MICs and were equal (61.5 %), one dilution higher (28.3 %), two dilutions higher (0.4 %), one dilution lower (9.5 %), and two dilutions lower (0.2 %) than M-BMD MICs. The mean PAP-AUC for Etest vs M-BMD among isolates with similar Etest/M-BMD MIC values was 0.25 ± 0.15 vs 0.35 ± 0.13 (p = 0.8), 0.46 ± 0.16 vs 0.50 ± 0.17 (p = 0.8), 0.64 ± 0.19 vs 0.67 ± 0.21 (p = 0.9), and 0.90 ± 0.31 vs 0.88 ± 0.25 (p = 1.0) for isolates with V-MIC of ≤1, 1.5, 2, and ≥3 mg/L respectively. These results suggest that Etest might not overestimate V-MIC in comparison to M-BMD or BMD; Etest and M-BMD tests depict comparable PAP-AUC and have a higher correlation with PAP-AUC than the conventional BMD, probably because of the more detailed results. Etest may be more suitable than conventional BMD for MIC outcome assessment because of the more detailed MICs.
Literatur
1.
Zurück zum Zitat Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K (2008) Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52:3315–3320PubMedCrossRef Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K (2008) Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52:3315–3320PubMedCrossRef
2.
Zurück zum Zitat Mason EO, Lamberth LB, Hammerman WA, Hulten KG, Versalovic J, Kaplan SL (2008) Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005. J Clin Microbiol 47:1628–1630CrossRef Mason EO, Lamberth LB, Hammerman WA, Hulten KG, Versalovic J, Kaplan SL (2008) Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005. J Clin Microbiol 47:1628–1630CrossRef
3.
Zurück zum Zitat Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ (2012) Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with high vancomycin minimum inhibitory concentration: a case–control study. Clin Infect Dis 54:51–58PubMedCrossRef Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ (2012) Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with high vancomycin minimum inhibitory concentration: a case–control study. Clin Infect Dis 54:51–58PubMedCrossRef
4.
Zurück zum Zitat Musta AC, Riederer K, Shemes S, Chase P, Jose J, Johnson LB, Khatib R (2009) Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol 47:1640–1644PubMedCrossRef Musta AC, Riederer K, Shemes S, Chase P, Jose J, Johnson LB, Khatib R (2009) Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol 47:1640–1644PubMedCrossRef
5.
Zurück zum Zitat Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM (2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42:2398–2402PubMedCrossRef Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM (2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42:2398–2402PubMedCrossRef
6.
Zurück zum Zitat Soriano A, Marco F, Martínez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J (2008) Influence of vanco- mycin minimal inhibitory concentration on the treatment of methicillin resistant Staphylococcus aureus bacteremia. Clin Infect Dis 46:193–200 Soriano A, Marco F, Martínez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J (2008) Influence of vanco- mycin minimal inhibitory concentration on the treatment of methicillin resistant Staphylococcus aureus bacteremia. Clin Infect Dis 46:193–200
7.
Zurück zum Zitat Khatib R, Jose J, Musta AC, Sharma M, Fakih MG, Johnson LB, Riederer K, Shemes S (2011) The relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteremia. J Antimicrob Chem 66:1594–1599CrossRef Khatib R, Jose J, Musta AC, Sharma M, Fakih MG, Johnson LB, Riederer K, Shemes S (2011) The relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteremia. J Antimicrob Chem 66:1594–1599CrossRef
8.
Zurück zum Zitat Sader HS, Rhomberg PR, Jines RN (2009) Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob Agent Chemother 53:3162–3165CrossRef Sader HS, Rhomberg PR, Jines RN (2009) Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob Agent Chemother 53:3162–3165CrossRef
9.
Zurück zum Zitat Prakash V, Lewis JS 2nd, Jorgensen JH (2008) Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother 52:4528PubMedCrossRef Prakash V, Lewis JS 2nd, Jorgensen JH (2008) Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother 52:4528PubMedCrossRef
10.
Zurück zum Zitat Jorgensen JH, Turnidge JD (2007) Susceptibility test methods: dilution and disk diffusion methods. Antibacterial agents and susceptibility test methods. In: Murray PR, Baron EJ, Jergensen JH, Landry ML, Pfaller MA (eds) Manual of clinical microbiology, 9th edn. ASM Press, Washington DC, pp 1152–1172 Jorgensen JH, Turnidge JD (2007) Susceptibility test methods: dilution and disk diffusion methods. Antibacterial agents and susceptibility test methods. In: Murray PR, Baron EJ, Jergensen JH, Landry ML, Pfaller MA (eds) Manual of clinical microbiology, 9th edn. ASM Press, Washington DC, pp 1152–1172
11.
Zurück zum Zitat European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) (2000) Determination of minimum inhibitory concentration (MICs) of antimicrobial agents by agar dilution. Clin Microbiol Infect 6:509–515CrossRef European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) (2000) Determination of minimum inhibitory concentration (MICs) of antimicrobial agents by agar dilution. Clin Microbiol Infect 6:509–515CrossRef
12.
Zurück zum Zitat Steinkraus G, White R, Friedrich L (2007) Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–05. J Antimicrob Chemother 60:788–794PubMedCrossRef Steinkraus G, White R, Friedrich L (2007) Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–05. J Antimicrob Chemother 60:788–794PubMedCrossRef
13.
Zurück zum Zitat Van Hall SB, Barbagiannakos T, Jones M, Wehrhahn MC, Mercer J, Chen D, Paterson DL, Gosbell IB (2011) Methicillin-resistant Staphylococcus aureus vancomycin susceptibility testing: methodology correlations, temporal trends and clonal patterns. J Antimicrob Chemother 66:2284–2287CrossRef Van Hall SB, Barbagiannakos T, Jones M, Wehrhahn MC, Mercer J, Chen D, Paterson DL, Gosbell IB (2011) Methicillin-resistant Staphylococcus aureus vancomycin susceptibility testing: methodology correlations, temporal trends and clonal patterns. J Antimicrob Chemother 66:2284–2287CrossRef
14.
Zurück zum Zitat Chua T, Moore CL, Perri MB, Donabedian SM, Masch W, Vager D, Davis SL, Lulek K, Zimnicki B, Zervos MJ (2008) Molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream isolates in urban Detroit. J Clin Microbiol 46:2345–2352PubMedCrossRef Chua T, Moore CL, Perri MB, Donabedian SM, Masch W, Vager D, Davis SL, Lulek K, Zimnicki B, Zervos MJ (2008) Molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream isolates in urban Detroit. J Clin Microbiol 46:2345–2352PubMedCrossRef
15.
Zurück zum Zitat Kruzel MC, Lewis CT, Welsh KJ, Lewis EM, Dundas NE, Mohr JF, Armitige LY, Wanger A (2011) Determination of vancomycin and daptomycin MICs by different testing methods for methicillin-resistant Staphylococcus aureus. J Clin Microbiol 49:2272–2273PubMedCrossRef Kruzel MC, Lewis CT, Welsh KJ, Lewis EM, Dundas NE, Mohr JF, Armitige LY, Wanger A (2011) Determination of vancomycin and daptomycin MICs by different testing methods for methicillin-resistant Staphylococcus aureus. J Clin Microbiol 49:2272–2273PubMedCrossRef
16.
Zurück zum Zitat Hsu DI, Hidayat LK, Quist R, Hindler J, Karlsson A, Yusof A, Wong-Beringer A (2008) Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of methicillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents 32:378–385PubMedCrossRef Hsu DI, Hidayat LK, Quist R, Hindler J, Karlsson A, Yusof A, Wong-Beringer A (2008) Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of methicillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents 32:378–385PubMedCrossRef
17.
Zurück zum Zitat Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP (2001) A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 47:399–403PubMedCrossRef Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP (2001) A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 47:399–403PubMedCrossRef
Metadaten
Titel
Correlation of methicillin-resistant Staphylococcus aureus vancomycin minimal inhibitory concentration results by Etest and broth microdilution methods with population analysis profile: lack of Etest overestimation of the MIC
verfasst von
R. Khatib
K. Riederer
S. Shemes
A. C. Musta
S. Szpunar
Publikationsdatum
01.06.2013
Verlag
Springer-Verlag
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 6/2013
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-012-1811-7

Weitere Artikel der Ausgabe 6/2013

European Journal of Clinical Microbiology & Infectious Diseases 6/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.